Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker CLDX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) NCT06455202 · Chronic Spontaneous Urticaria barzolvolimab, Matching placebo | CLDX Celldex Therapeutics | Phase 3 | Active, not recruiting | 976 | Aug 4, 2026 | Registry ↗ |
| Nov 12, 2026 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria NCT06445023 · Chronic Spontaneous Urticaria barzolvolimab, Matching placebo | CLDX Celldex Therapeutics | Phase 3 | Active, not recruiting | 963 | Aug 12, 2026 | Registry ↗ |
| Nov 2, 2026 | A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults… NCT07266402 · Chronic Inducible Urticaria, Cold Urticaria Barzolvolimab, Matching Placebo | CLDX Celldex Therapeutics | Phase 3 | Recruiting | 240 | Jun 2028 | Registry ↗ |
| Nov 2, 2026 | Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic S… NCT07256392 · Chronic Spontaneous Urticaria barzolvolimab, Standard of Care | CLDX Celldex Therapeutics | Phase 3 | Enrolling by invitation | 1,370 | Sep 2028 | Registry ↗ |
| Aug 11, 2026 | A Study of Barzolvolimab in Patients With Atopic Dermatitis NCT06727552 · Atopic Dermatitis Barzolvolimab, Matching placebo | CLDX Celldex Therapeutics | Phase 2 | Active, not recruiting | 131 | May 6, 2026 | Registry ↗ |
| Aug 4, 2026 | A Study of Barzolvolimab in Patients With Prurigo Nodularis NCT06366750 · Prurigo Nodularis barzolvolimab, Matching Placebo | CLDX Celldex Therapeutics | Phase 2 | Active, not recruiting | 140 | Mar 17, 2026 | Registry ↗ |
| Jul 2, 2026 | A Study of CDX-622 in Participants With Mild to Moderate Asthma NCT07330778 · Mild to Moderate Asthma CDX-622 | CLDX Celldex Therapeutics | Phase 1 | Recruiting | 12 | Mar 2027 | Registry ↗ |
| May 27, 2026 | A Study of CDX-0159 in Patients With Eosinophilic Esophagitis NCT05774184 · Eosinophilic Esophagitis barzolvolimab, Matching Placebo | CLDX Celldex Therapeutics | Phase 2 | Completed | 86 | Jun 4, 2025 | Registry ↗ |
| May 4, 2026 | A Phase I Study of CDX-622 NCT06650761 · Healthy Participants CDX-622, Normal Saline | CLDX Celldex Therapeutics | Phase 1 | Completed | 85 | Apr 24, 2026 | Registry ↗ |
| Nov 6, 2025 | A Study of CDX-0159 in Patients With Chronic Inducible Urticaria NCT05405660 · Chronic Inducible Urticaria barzolvolimab, Matching Placebo | CLDX Celldex Therapeutics | Phase 2 | Completed | 196 | Jun 12, 2024 | Registry ↗ |
| Jun 15, 2025 | A Study of CDX-585 in Patients With Advanced Malignancies NCT05788484 · Non-small Cell Lung Cancer, Gastric Cancer CDX-585 | CLDX Celldex Therapeutics | Phase 1 | Completed | 20 | May 21, 2025 | Registry ↗ |
| Mar 26, 2025 | A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria NCT05368285 · Chronic Spontaneous Urticaria barzolvolimab, Matching Placebo | CLDX Celldex Therapeutics | Phase 2 | Completed | 208 | Sep 28, 2023 | Registry ↗ |
| Mar 28, 2024 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies NCT03329950 · Melanoma, Non-small Cell Lung Cancer CDX-1140, CDX-301 | CLDX Celldex Therapeutics | Phase 1 | Completed | 132 | Sep 13, 2022 | Registry ↗ |
| Feb 7, 2024 | Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem… NCT05017298 · Corona Virus Infection, Covid19 Allogeneic adipose-derived stem cells | CLDX Celltex Therapeutics Corporation | Phase 2 | Not yet recruiting | 30 | Nov 1, 2024 | Registry ↗ |
| Feb 7, 2024 | Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease NCT04855955 · Alzheimer Disease Adipose-Derived Mesenchymal Stem Cells | CLDX Celltex Therapeutics Corporation | — | No longer available | — | — | Registry ↗ |
| Aug 14, 2023 | A Study of CDX-0159 in Patients With Prurigo Nodularis NCT04944862 · Prurigo Nodularis CDX-0159, Normal saline | CLDX Celldex Therapeutics | Phase 1 | Completed | 24 | Jul 31, 2023 | Registry ↗ |
| Jul 19, 2023 | A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria NCT04538794 · Chronic Spontaneous Urticaria CDX-0159, Normal Saline | CLDX Celldex Therapeutics | Phase 1 | Completed | 45 | Jan 17, 2023 | Registry ↗ |
| Jun 18, 2023 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies NCT04440943 · Non-small Cell Lung Cancer, Breast Cancer CDX-527 | CLDX Celldex Therapeutics | Phase 1 | Completed | 27 | Apr 6, 2023 | Registry ↗ |
| May 17, 2023 | A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients Wi… NCT04548869 · Cold Urticaria, Cold Contact Urticaria CDX-0159 | CLDX Celldex Therapeutics | Phase 1 | Completed | 41 | Dec 16, 2022 | Registry ↗ |
| Apr 18, 2023 | Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis NCT04448106 · Osteoarthritis, Knee, Osteoarthritis, Hip Celltex- AdMSCs | CLDX Celltex Therapeutics Corporation | Phase 2 | Unknown | 300 | Aug 1, 2024 | Registry ↗ |
| Apr 18, 2023 | Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 NCT04428801 · COVID-19 autologous adipose-derived stem cells | CLDX Celltex Therapeutics Corporation | Phase 2 | Unknown | 200 | Sep 2024 | Registry ↗ |
| Apr 18, 2023 | Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis NCT04170426 · Rheumatoid Arthritis autologous adipose derived stem cells | CLDX Celltex Therapeutics Corporation | Phase 1/2 | Not yet recruiting | 54 | Dec 2024 | Registry ↗ |
| Apr 3, 2023 | A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcino… NCT03254927 · Advanced Head and Neck Squamous Cell Carcinoma CDX-3379 and cetuximab | CLDX Celldex Therapeutics | Phase 2 | Terminated | 30 | Sep 16, 2020 | Registry ↗ |
| Jan 21, 2022 | A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects NCT05031624 · Healthy Subjects CDX-0159, Normal saline | CLDX Celldex Therapeutics | Phase 1 | Completed | 32 | Jan 14, 2022 | Registry ↗ |
| Jul 7, 2020 | A Phase 1 Study of CDX-0159 NCT04146129 · Healthy Subjects CDX-0159, Normal saline | CLDX Celldex Therapeutics | Phase 1 | Completed | 32 | Apr 6, 2020 | Registry ↗ |
| Jun 4, 2020 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and O… NCT02837991 · Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma CDX-014 | CLDX Celldex Therapeutics | Phase 1 | Terminated | 16 | Nov 16, 2018 | Registry ↗ |
| Feb 17, 2020 | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma NCT01498328 · Glioblastoma, Small Cell Glioblastoma Bevacizumab, Rindopepimut (CDX-110) with GM-CSF | CLDX Celldex Therapeutics | Phase 2 | Completed | 127 | Apr 2015 | Registry ↗ |
| Feb 13, 2020 | A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Ca… NCT01094496 · Bladder Cancer CDX-1307 Vaccine Regimen, Chemotherapy | CLDX Celldex Therapeutics | Phase 2 | Terminated | 3 | Jul 2011 | Registry ↗ |
| Dec 9, 2019 | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in… NCT02335918 · Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovari… Combination of varlilumab and nivolumab | CLDX Celldex Therapeutics | Phase 1/2 | Completed | 175 | Dec 12, 2018 | Registry ↗ |
| Sep 6, 2019 | A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients… NCT02302339 · Melanoma glembatumumab vedotin, glembatumumab vedotin and varlilumab | CLDX Celldex Therapeutics | Phase 2 | Terminated | 132 | Jun 14, 2018 | Registry ↗ |
| Aug 1, 2019 | A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients NCT02473731 · Squamous Cell Carcinoma of the Head and Neck KTN3379 | CLDX Celldex Therapeutics | Phase 1 | Completed | 12 | Sep 22, 2016 | Registry ↗ |
| Jun 12, 2019 | A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Sol… NCT02642016 · Advanced Cancer CDX-0158 (formerly known as KTN-0158) | CLDX Celldex Therapeutics | Phase 1 | Completed | 28 | Jan 30, 2018 | Registry ↗ |
| Mar 8, 2019 | Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple… NCT01997333 · Metastatic gpNMB Over-expressing Triple Negative Breast Can… CDX-011, Capecitabine | CLDX Celldex Therapeutics | Phase 2 | Completed | 327 | Nov 30, 2017 | Registry ↗ |
| Jul 26, 2018 | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell C… NCT02386111 · Carcinoma, Renal Cell, Kidney Diseases Combination of varlilumab and sunitinib | CLDX Celldex Therapeutics | Phase 1 | Terminated | 17 | Aug 2017 | Registry ↗ |
| May 21, 2018 | Individual Patient Expanded Access-Glembatumumab Vedotin NCT03067935 · Metastatic gpNMB Expressing Triple Negative Breast Cancer glembatumumab vedotin | CLDX Celldex Therapeutics | — | No longer available | — | — | Registry ↗ |
| Apr 30, 2018 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer NCT02543645 · Carcinoma, Renal Cell, Kidney Diseases Combination of Varlilumab and Atezolizumab | CLDX Celldex Therapeutics | Phase 1 | Terminated | 18 | Apr 2017 | Registry ↗ |
| Jan 31, 2018 | A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers NCT01460134 · CD27 Expressing B-cell Malignancies for Example Hodgkin's L… CDX-1127, CDX-1127 | CLDX Celldex Therapeutics | Phase 1 | Completed | 90 | Dec 2015 | Registry ↗ |
| Jan 16, 2018 | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma NCT01480479 · Glioblastoma, Small Cell Glioblastoma Rindopepimut (CDX-110) with GM-CSF, Temozolomide | CLDX Celldex Therapeutics | Phase 3 | Completed | 745 | Nov 2016 | Registry ↗ |
| Jan 16, 2018 | Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme NCT00458601 · Malignant Glioma CDX-110 with GM-CSF, Temozolomide | CLDX Celldex Therapeutics | Phase 2 | Completed | 82 | Nov 2010 | Registry ↗ |
| Oct 18, 2017 | Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut NCT03068650 · Recurrent GBM rindopepimut | CLDX Celldex Therapeutics | — | No longer available | — | — | Registry ↗ |
| Sep 5, 2017 | Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemura… NCT02456701 · Thyroid Cancer KTN3379, vemurafenib | CLDX Celldex Therapeutics | Phase 1 | Completed | 7 | Oct 13, 2016 | Registry ↗ |
| Jul 24, 2017 | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advan… NCT02014909 · Advanced Cancer KTN3379 | CLDX Celldex Therapeutics | Phase 1 | Completed | 64 | May 25, 2017 | Registry ↗ |
| Jul 2, 2017 | A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer NCT01156753 · Breast Cancer CDX-011, "Investigator's Choice" chemotherapy | CLDX Celldex Therapeutics | Phase 2 | Completed | 120 | Oct 2012 | Registry ↗ |
| Jun 27, 2017 | A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers NCT01465139 · Healthy CDX-301 | CLDX Celldex Therapeutics | Phase 1 | Completed | 30 | Nov 2012 | Registry ↗ |
| Apr 7, 2017 | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage I… NCT02413827 · Unresectable Stage III or Stage IV Melanoma Combination of varlilumab and ipilimumab, Cohort A: varlilu… | CLDX Celldex Therapeutics | Phase 1/2 | Terminated | 9 | Nov 2, 2016 | Registry ↗ |
| Apr 7, 2017 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in… NCT02200380 · For Donors, Related Donors Giving Peripheral Blood Stem Cel… CDX-301, CDX-301 and plerixafor | CLDX Celldex Therapeutics | Phase 2 | Terminated | 36 | Mar 2016 | Registry ↗ |
| Jun 27, 2016 | A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 NCT00948961 · Advanced Malignancies CDX-1401 in combination with Resiquimod and/or Poly-ICLC, C… | CLDX Celldex Therapeutics | Phase 1/2 | Completed | 70 | Jun 2012 | Registry ↗ |
47 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:40 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances